Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report) dropped 13.4% on Tuesday . The stock traded as low as $19.79 and last traded at $19.79. Approximately 600 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 1,521 shares. The stock had previously closed at $22.85.
Santhera Pharmaceuticals Stock Performance
The business has a 50-day moving average of $23.11 and a two-hundred day moving average of $22.24.
Santhera Pharmaceuticals Company Profile
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.
The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON).
Further Reading
- Five stocks we like better than Santhera Pharmaceuticals
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
